Is Alterity Therapeutics Limited (ATHE) a Buy, Sell, or Hold?
NASDAQ : ATHE
Alterity Therapeutics Limited
$4.98 USD
-$0.1 (-2.06%)
- Volume
- 4.43K
- Average Volume
- 52.48K
- Market Capitalization
- $45.14M
- P/E Ratio
- -7.20
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $7.00
- Year Low
- $2.66
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $21.98
Company Overview
NASDAQ
David A. Stamler
Biotechnology
Healthcare
ATHE
9
AU
USD
Liquidity Metrics
0.00
21.98
21.98
19.03
0.00
Sales & Valuation
$5.44M
33.48
2.21
-54.49
-6.94
Profitability
-$1.14
-$12.15M
-380.65%
-450.41%
-30.19%
-25.63%
P/E Metrics
-7.20
-0.10
-0.10
Analyst Price Target & Rating
2/5
8 Analysts
%
Poll Results
About Alterity Therapeutics Limited (NASDAQ:ATHE) Stock
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia. ...
2026-07-07 07:05:00
– Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide additional detail on the planned Phase 3 protocol —
Alterity Therapeutics Advances Lead Drug Towards Pivotal Study For Rare Neuromuscular Disorder
2026-06-09 11:41:42
Alterity Therapeutics Limited (NASDAQ:ATHE) stock is up during Tuesday's session as the biotechnology company announced an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding its pivotal Phase 3 program for ATH434 in treating Multiple System Atrophy (MSA).
2026-06-09 07:05:00
– Successful End-of-Phase 2 meeting with FDA agreeing on key elements of the proposed Phase 3 design, including study population, dosing regimen, and treatment duration –
2026-05-19 07:25:00
– Alterity's novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA –
2026-05-11 07:25:00
– Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disease-specific iron accumulation that supports diagnosis and correlates with clinical severity in patients with Multiple System Atrophy (MSA) –
Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
2026-05-07 07:25:00
MELBOURNE, Australia and SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that presentations related to the Company's development program in Multiple System Atrophy (MSA) will be delivered at multiple medical conferences in May 2026.
Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
2026-04-30 07:25:00
Highlights Aligned with the FDA in two Positive Type C meetings supporting key elements of the planned Phase 3 program for ATH434 in MSA Advancing ATH434 toward pivotal Phase 3 program; on track for End-of-Phase 2 FDA meeting mid-year 2026 Late breaking platform presentation at American Academy of Neurology annual meeting demonstrated consistent evidence of efficacy and reinforces ATH434's clinical profile Strengthened clinical leadership with appointment of Dr. Daniel Claassen as Chief Medical Advisor Enhanced Board of Directors with appointment of Ms. Ann Cunningham, bringing extensive global commercial and neurodegenerative disease expertise Hosted a virtual KOL event featuring leading experts to highlight clinical progress on MSA program and reinforce the scientific rationale for ATH434 Alterity continues to engage in discussions with a number of pharmaceutical companies regarding potential strategic collaboration opportunities for ATH434 Cash balance of A$44.53 million at 31 March 2026 MELBOURNE, Australia and SAN FRANCISCO, April 30, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31 March 2026 (Q3 FY26).
2026-04-28 20:41:52
Alterity Therapeutics Limited (ATHE) Discusses Phase II Data and Development Strategy for ATH434 in Multiple System Atrophy Transcript
Frequently Asked Questions
-
What is the current Alterity Therapeutics Limited (ATHE) stock price?
-
Alterity Therapeutics Limited(NASDAQ:ATHE) stock price is $4.98 in the last trading session. During the trading session, ATHE stock reached the peak price of $7 while $2.66 was the lowest point it dropped to. The percentage change in ATHE stock occurred in the recent session was --2.06% while the dollar amount for the price change in ATHE stock was -$0.1.
-
ATHE's industry and sector of operation?
-
The NASDAQ listed ATHE is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ATHE?
-
Rudolph Emile Tanzi | Chief Scientific Advisor and Member of Research & Development Advisory Board
David A. Stamler | CEO & Director
Robert Cherny | Head of Research
Abby Macnish Niven | Chief Financial Officer & Company Secretary
Steven D. Targum | Chief Medical Advisor -
How many employees does ATHE have?
-
Number of ATHE employees currently stands at 9. ATHE operates from 460 Bourke Street, Melbourne, VIC 3000, AU.
-
Link for ATHE official website?
-
Official Website of ATHE is: https://alteritytherapeutics.com
-
How do I contact ATHE?
-
ATHE could be contacted at phone #61 3 9349 4906 and can also be accessed through its website. ATHE operates from 460 Bourke Street, Melbourne, VIC 3000, AU.
-
How many shares of ATHE are traded daily?
-
The average number of ATHE shares traded daily for last 3 months was 52.48K.
-
What is the market cap of ATHE currently?
-
The market value of ATHE currently stands at $45.14M with its latest stock price at $4.98